Science Corporation Implants Vision-Restoring Chip in First Stargardt Patient, Unveiling a Broader BCI Vision

Science Corporation CEO Max Hodak, former president and co-founder of Neuralink, made a significant announcement at TechCrunch Disrupt: his company has successfully implanted its vision-restoring chip, PRIMA, into its first patient suffering from Stargardt disease. This move marks a critical step not only for those battling the inherited eye condition but also for Hodak’s ambitious vision of brain-computer interfaces (BCIs) extending far beyond traditional control systems, into a vast landscape of medical innovation.

Key Takeaways

• First-in-Human for Stargardt:Science Corporation has successfully implanted its PRIMA vision-restoring chip into a patient with Stargardt disease, an inherited condition causing central vision loss, marking a major milestone for an incurable condition.
• Vision as a BCI Frontier:CEO Max Hodak emphasizes that retinal prostheses like PRIMA are fundamental BCIs, signaling the company’s strategy to prove its neural engineering methods and build a sustainable business through accessible medical applications before pursuing broader, more complex brain interfaces.
• Ambitious Future Roadmap:Beyond current visual restoration, Science Corporation envisions next-generation implants offering near-native acuity within five years and is actively developing skull-mounted BCIs for neurodegenerative diseases, stroke recovery, and ultimately, understanding and engineering the human mind to extend “health span.”

At the heart of Science Corporation’s groundbreaking work is PRIMA, a sophisticated implant designed to mimic the eye’s natural photoreceptors. While already commercially available in Europe for patients with geographic atrophy, an advanced form of age-related macular degeneration, the recent Stargardt disease implant represents a new frontier. Stargardt disease, an inherited condition affecting approximately 150,000 people worldwide, gradually destroys central vision by causing the death of light-sensing cells in the outer retina, often sparing the inner retina that transmits signals to the brain. For those afflicted, a central blind spot emerges, inexorably expanding over time.

“The retina is part of the central nervous system,” Hodak stated, framing the significance of their work. “We consider cochlear implants, retinal prostheses, motor prostheses, these are all different types of BCIs.” This perspective reframes vision restoration not merely as an ophthalmological procedure, but as a foundational step in a much grander endeavor to harness the brain’s electrical potential. Hodak elaborated on this philosophy, noting, “vision is electrical potential, like electrical activity down the optic nerve. That’s all vision is to the brain, and so if you can get the optic nerve to signal the rest of the brain correctly, then you can provide vision to it.”

The pioneering patient with Stargardt disease received the PRIMA implant in May as part of an ongoing trial at the Sydney Eye Hospital in Australia. The results, though preliminary, are nothing short of remarkable. During the initial rehabilitation session, the patient was able to discern a letter. By the second session, they had progressed to reading an entire word, offering a tangible glimpse into a future where sight can be reclaimed.

Engineering Vision: How PRIMA Works and Its Future Iterations

The implantation process itself is a testament to modern medical precision, involving an hour-long procedure to place a minuscule chip in the back of the patient’s eye, specifically where the natural photoreceptors have deteriorated. Once implanted, patients wear specialized camera-equipped glasses that capture the surrounding world and wirelessly transmit this visual information to the chip. In essence, the implant acts as an array of artificial photoreceptors, converting light into electrical signals that the optic nerve can then relay to the brain.

Hodak was candid about the current capabilities and limitations of the device. “The device that this patient has is a two millimeter by two millimeter implant placed under the in the back of the eye, and so it’s like looking through a straw,” he explained. “It is not a big field of view color vision. It’s a patch in their central vision where . . .it’s black and white, but it is sharp. It’s high-contrast sharp, and so they can see a couple letters at a time.”

However, the vision for PRIMA extends far beyond its current iteration. Hodak outlined a clear development path for future generations. “The next step is to make the field of view bigger. So to make a bigger implant, you have to deal with the curvature of the eye, and we need to make the electrodes smaller so that we get closer to native levels of detail,” he elaborated. This iterative approach is ambitious, with Hodak confidently predicting, “I think we have a clear path. There’s a there’s a next ‘next generation’ that’s being worked on that’ll be in humans in the next year, and over the next five years, I think we’ll be able to get pretty close to native acuity.”

Science Corporation’s Grand Vision: BCI and the Future of Human Health

When Max Hodak founded Science Corporation in 2021, following his departure from Neuralink, the overarching mission was clear: to develop advanced neural engineering and brain-computer interface technology. However, the pragmatic approach involved establishing a sustainable business and proving their methods through tangible, impactful applications. Restoring vision for the visually impaired served as that crucial first step.

Distinct from some other BCI approaches, Science Corporation’s broader brain-computer interface technology is designed differently. While Neuralink’s devices are inserted directly into brain tissue, Science Corporation’s sensor will be implanted inside the skull but will rest *on top* of the brain. This design choice aims to offer robust functionality while potentially mitigating some of the invasive risks associated with direct brain penetration.

The potential applications of this broader BCI technology are vast and deeply medically focused. Science Corporation believes its devices could help address a range of neurological conditions, from monitoring activity in patients with brain tumors to aiding recovery from stroke. “In the near term, we’re going to be applying our first clinical indication, which hasn’t been announced publicly, is a neurodegenerative disease that everybody’s heard of,” Hodak hinted. He further mused on the radical possibilities for stroke patients: “For example, if you’ve lost part of your brain because it’s been dead due to stroke, if you can get connections into the deep brain in two different areas, you can imagine adding new cortical areas, just like adding new brain areas entirely — something simply not possible with conventional electrodes.”

Ultimately, Hodak articulated an even grander, long-term mission: “the long-term mission of the company is to understand how the brain creates the mind and to learn to build engineered brains.” This audacious goal speaks to the very essence of human consciousness and the potential for technology to not only restore function but perhaps even augment human cognitive capabilities.

Looking further into the future, Hodak expressed a belief that BCIs will become increasingly commonplace as populations age. While Science Corporation isn’t currently designing for “healthy 40-year-olds,” he projected that by the age of 60 or 70, a significant portion of the population might find some form of BCI beneficial. This future-gazing aligns with the company’s core philosophy: “We want to figure out how do we extend not just lifespan but health span.”

The Bottom Line

Science Corporation’s successful PRIMA implant in a Stargardt patient represents a monumental leap in vision restoration and a powerful proof-of-concept for the broader potential of brain-computer interfaces. Under Max Hodak’s leadership, the company is meticulously building a foundation from impactful medical applications like artificial vision towards an ambitious future of neural engineering. By prioritizing both immediate patient benefit and a long-term vision to understand and enhance the human mind, Science Corporation is positioning itself at the forefront of a technological revolution that promises to redefine human health and capabilities, extending not just life, but the quality of life itself. The journey from restoring sight to engineering cognition is long, but the initial steps are now firmly in place.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.